(Reuters) – Britain’s GSK and South Korea’s SK Bioscience said on Tuesday the drugmakers have begun a late-stage trial of their COVID-19 vaccine candidate to assess immune response when compared with AstraZeneca’s approved shot.
The trial will enrol around 4,000 candidates globally and test SK’s COVID-19 vaccine candidate, GBP510, in combination with GSK’s vaccine booster following positive early-stage data https://www.skbioscience.co.kr/en/news/news_01_01?mode=view&id=91& earlier this month.
Don't miss out on any breaking news or insightful opinions!
Subscribe to our free newsletter and stay updated on the go!
By submitting this form, you are consenting to receive marketing emails from: Global Banking & Finance Review. You can revoke your consent to receive emails at any time by using the SafeUnsubscribe® link, found at the bottom of every email.
Results from the GSK-SK study are expected in the first half next year, and the vaccine will be supplied worldwide through the World Health Organization-led vaccine sharing programme COVAX if approved, the companies said.
(Reporting by Pushkala Aripaka in Bengaluru; Editing by Shounak Dasgupta)
Craig Upton supports UK businesses by increasing sales growth using various marketing solutions online. Creating strategic partnerships and keen focus to detail, Craig equips websites with the right tools to rank in organic search. Craig is also the CEO of iCONQUER, a UK based SEO Agency and has been working in the digital marketing arena for many years. A trusted SEO consultant and trainer, Craig has worked with British brands such as FT.com, djkit.com, Development Finance, Serimax and has also supported UK doctors, solicitors and property developers to gain more exposure online. Craig has gained a wealth of knowledge using Google and is committed to creating new opportunities and partnerships.
